Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: Results from CaPSURE
Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: Results from CaPSURE
复制标题
DOI：
10.1097/01.ju.0000091993.73842.9b
复制
发表时间：
2003-11-01
影响因子：
6.6
通讯作者：
Litwin, MS
中科院分区：
文献类型：
--
作者：
Mehta, SS;Lubeck, DP;Litwin, MS
目的：现代癌症治疗延长了患者的寿命，但增加了疾病复发的风险。研究表明，对复发的恐惧是一种重大负担。我们描述了接受根治性前列腺切除术(RP)、放射治疗(XRT)或近距离放射治疗(BT)的前列腺癌患者对癌症复发的恐惧。材料和方法：总共519名患者(326名RP，53名XRT，140名BT)来自前列腺癌战略泌尿研究奋进中心(CaPSURE)，这是一项关于前列腺癌男性的国家纵向登记。要纳入这项研究，患者必须完成至少1份治疗前和2份治疗后与健康相关的生活质量问卷，并拥有完整的临床信息。对癌症复发的恐惧用有效的5项量表进行评估，并在基线和治疗后最多2年进行描述。结果：接受放射治疗的男性比接受RP或BT治疗的患者年龄更大，临床疾病特征更差。对于所有组，对癌症复发的恐惧在治疗前更加严重，治疗后有所改善，但在此后的两年中没有实质性改变。回归分析显示，只有一般健康状况和精神健康状况是癌症复发恐惧的重要预测因素。没有其他一般或疾病特定的健康相关生活质量领域或临床特征提供了显著的解释力。结论：前列腺癌复发的恐惧在治疗前后给患者带来了巨大的负担。了解与不同治疗相关的癌症复发恐惧，可以帮助医生更好地为患者提供咨询，并促进心理健康。
Purpose: Contemporary cancer treatments have resulted in patients living longer but with the risk of disease recurrence. Studies suggest that fear of recurrence is a significant burden. We described fear of cancer recurrence in patients with prostate cancer undergoing treatment with radical prostatectomy (RP), radiation (XRT) or brachytherapy (BT).Materials and Methods: A total of 519 patients (326 RP, 53 XRT, 140 BT) were identified from CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor), a national longitudinal registry of men with prostate cancer. To be included in the study patients had to complete at least 1 pretreatment and 2 posttreatment health related quality of life questionnaires and have complete clinical information. Fear of cancer recurrence was assessed with a validated 5-item scale, and was described at baseline and up to 2 years after treatment. Multivariate linear regression was performed to determine significant predictors of fear of cancer recurrence.Results: Men receiving XRT were older and had worse clinical disease characteristics than patients treated with RP or BT. For all groups fear of cancer recurrence was more severe before treatment and improved after treatment but did not change substantially in the 2 years thereafter. Regression revealed that only general health and mental health were important predictors of fear of cancer recurrence. No other general or disease specific health related quality of life domains or clinical characteristics contributed appreciable explanatory power.Conclusions: Fear of prostate cancer recurrence imposes a substantial burden in patients before and after treatment. Understanding the fear of cancer recurrence associated with different treatments can help physicians better counsel patients and promote psychological well-being.